

AMENDMENT

Listing of Claims

The following listing of claims replaces all previous listings or versions thereof:

1. (Currently amended) A method for diagnosing risk of spontaneous abortion comprising:
~~providing contact between (a) contacting a sample of body fluid and with an antigen capable of binding to an antibody to platelet activating factor (PAF), and (b) assessing the presence and/or concentration of said antibodies to PAF and/or of antibodies to an antigen capable of binding to antibodies to PAF in the sample of body fluid by measuring antibodies bound to said antigen; and (c) evaluating said diagnosing the risk of spontaneous abortion based on the presence and/or concentration of said antibodies to PAF and/or of antibodies to an antigen capable of binding to antibodies to PAF in said sample of body fluid as an indicator of risk of spontaneous abortion.~~
2. (Currently amended) The method of claim 1, comprising wherein measuring the presence and/or concentration of antibodies to PAF and/or antibodies to an antigen capable of binding to antibodies to PAF by comprises an immunoassay.
3. (Currently amended) The method of claim 1, comprising wherein measuring the presence and/or concentration of antibodies to PAF and/or of antibodies to an antigen capable of binding to antibodies to PAF by comprises an enzyme linked immunosorbent assay.
4. (Currently amended) The method of claim 1, comprising wherein measuring the presence and/or concentration of antibodies to PAF and/or of antibodies to an antigen capable of binding to antibodies to PAF by comprises a radioimmunoassay.
5. (Currently amended) The method of claim 1, comprising measuring the presence and/or concentration of antibodies to PAF and/or antibodies to an antigen capable of binding to antibodies to PAF in wherein said body fluid is serum prepared from a blood sample.

6. (Currently amended) The method of claim 1, comprising measuring the presence and/or concentration of antibodies to PAF and/or of antibodies to an antigen capable of binding to antibodies to PAF in wherein said body fluid is plasma prepared from a blood sample.
7. (Currently amended) The method of claim 1, wherein said sample of body fluid is a human blood sample or fraction thereof, and the measuring of antibodies to PAF and/or of antibodies capable of binding to antibodies to PAF is by comprises an immunoassay.
8. (Currently amended) The method of claim 1, wherein said antigen capable of binding to antibodies to PAF is phospholcholine.

9-10. (Canceled)

11. (Currently amended) The method of claim 1, wherein said antigen capable of binding to antibodies to PAF is lysophosphatidylcholine.

12-23. (Canceled)